| Double-Expressor Lymphoma studied in …STUDIED_INderived11 of 11show fewer |
|---|
| → studied in | NCT05600686Phase 2 · active not recruiting Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 11 trials mapped (8 active) | — | — | Double-Expressor Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03984448Phase 2/Phase 3 · active not recruiting Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas · condition mapped ONTOLOGY_EXACT · 11 trials mapped (8 active) | — | — | Double-Expressor Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07069699Phase 1/Phase 2 · recruiting Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene · condition mapped ONTOLOGY_EXACT · 11 trials mapped (8 active) | — | — | Double-Expressor Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07511114Phase 3 · not yet recruiting A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyping · condition mapped ONTOLOGY_EXACT · 11 trials mapped (8 active) | — | — | Double-Expressor Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04479267Phase 2 · active not recruiting Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma · condition mapped ONTOLOGY_EXACT · 11 trials mapped (8 active) | — | — | Double-Expressor Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06891157Phase 2 · recruiting Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes · condition mapped ONTOLOGY_EXACT · 11 trials mapped (8 active) | — | — | Double-Expressor Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06674096Phase 2 · recruiting RLC Followed by CR-CHOP in Elderly Patients with Newly-diagnosed DEL · condition mapped ONTOLOGY_EXACT · 11 trials mapped (8 active) | — | — | Double-Expressor Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06652152not yet recruiting Mechanism Investigation of R-CHOP Regimen or Tucidinostat Plus R-CHOP (CR-CHOP) Regimen in the Treatment of BCL2/MYC Protein Double Expressor Lymphoma · condition mapped ONTOLOGY_EXACT · 11 trials mapped (8 active) | — | — | Double-Expressor Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04164368Phase 2 · completed Lenalidomide Combined With R-CHOP(R2-CHOP) in Newly Diagnosed Double-expressor Diffuse Large B-Cell Lymphoma Patients · condition mapped ONTOLOGY_EXACT · 11 trials mapped (8 active) | — | — | Double-Expressor Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01742988Phase 1 · completed Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma · condition mapped ONTOLOGY_EXACT · 11 trials mapped (8 active) | — | — | Double-Expressor Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03197259unknown Chronic Lymphocytic Leukemia Registry Study - Multicenter Prospective National Study · condition mapped ALIAS · 11 trials mapped (8 active) | — | — | Double-Expressor Lymphoma | 1 | Observed | clinicaltrials | graph → |